BR100 Increased By (0.36%)
BR30 Decreased By (-0.13%)
KSE100 Increased By (0.22%)
KSE30 Increased By (0.37%)
AGHA 6.68 Increased By ▲ 0.01 (0.15%)
BECO 4.37 No Change ▼ 0.00 (0%)
BML 57.32 Increased By ▲ 0.88 (1.56%)
BOP 30.35 Increased By ▲ 0.01 (0.03%)
CNERGY 13.12 Increased By ▲ 0.03 (0.23%)
CSIL 5.41 Increased By ▲ 0.05 (0.93%)
FCCL 52.79 Increased By ▲ 0.41 (0.78%)
FFL 14.72 Decreased By ▼ -0.02 (-0.14%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.09 No Change ▼ 0.00 (0%)
KOSM 5.73 Increased By ▲ 0.77 (15.52%)
LOTCHEM 26.46 Decreased By ▼ -0.89 (-3.25%)
MLCF 93.16 Increased By ▲ 0.41 (0.44%)
NBP 164.66 Decreased By ▼ -0.32 (-0.19%)
NCPL 55.66 Increased By ▲ 0.02 (0.04%)
NPL 61.16 Decreased By ▼ -0.10 (-0.16%)
OGDC 316.73 Decreased By ▼ -1.03 (-0.32%)
PACE 9.87 Decreased By ▼ -0.06 (-0.6%)
PAEL 35.63 Increased By ▲ 0.13 (0.37%)
PIBTL 14.68 Increased By ▲ 0.11 (0.75%)
PPL 226.91 Decreased By ▼ -0.88 (-0.39%)
PRL 93.02 Increased By ▲ 0.45 (0.49%)
PTC 60.26 Decreased By ▼ -0.37 (-0.61%)
SSGC 23.81 Increased By ▲ 0.01 (0.04%)
TBL 8.75 Increased By ▲ 0.07 (0.81%)
TELE 7.80 Increased By ▲ 0.02 (0.26%)
TPL 22.35 Increased By ▲ 0.12 (0.54%)
TPLP 12.97 Increased By ▲ 0.30 (2.37%)
TREET 22.16 Decreased By ▼ -0.38 (-1.69%)
TRG 56.56 Decreased By ▼ -1.24 (-2.15%)
Business & Finance

Moderna to deliver 25 million COVID-19 vaccine doses to Australia

  • It has been trying to speed up the rollout of jabs after it was stalled by supply hold-ups in Europe and concerns about blood clots tied to the AstraZeneca shot.
  • The deal also includes the supply of 15 million doses of Moderna's updated variant booster vaccine candidate to be delivered in 2022, the company said.
Published Updated
By

Moderna Inc will supply Australia 25 million doses of its COVID-19 vaccine, of which 10 million doses against the original strain of the virus will be delivered this year, the drugmaker said on Wednesday.

Australia currently has two authorized vaccines from Pfizer-BioNTech and AstraZeneca.

It has been trying to speed up the rollout of jabs after it was stalled by supply hold-ups in Europe and concerns about blood clots tied to the AstraZeneca shot.

The deal also includes the supply of 15 million doses of Moderna's updated variant booster vaccine candidate to be delivered in 2022, the company said.

The pact with Moderna is subject to regulatory approval of its vaccine candidate, which is authorized for emergency use in individuals 18 years of age or older in the United States.

Moderna has also received authorization for its vaccine from health agencies including Canada, Israel, the European Union, the United Kingdom and Switzerland.

Comments

Comments are closed for this article.